IP Library Granted Patent US 8,524,739
Granted Patent B2
US 8,524,739 · App. 13/093,261 · Granted Sep 3, 2013

Quinoline derivatives and uses thereof

Inventors: David H. Peyton (Portland, OR); Steven Burgess (Tualatin, OR)
Assignee: State of Oregon acting by and through the State Board of Higher Education on behalf of Portland State University
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,524,739
App. No.
13/093,261
Granted
Sep 3, 2013
Kind
B2
Abstract

This disclosure provides a new class of compounds referred to as “reversed chloroquines” (RCQs), which are highly effective against CQ R and CQ S malaria parasites. RCQs are hybrid molecules, which include an antimalarial quinoline analog (such as chloroquine) moiety and a CQ R reversal moiety. Exemplary RCQ chemical structures are provided. Also provided are pharmaceutical compositions including the disclosed RCQ compounds, and methods of using such compounds and compositions for the treatment of malaria and inhibition of CQ R or CQ S Plasmodium sp. (such as P. falciparum ).

Claims (14)

1. A compound having the formula

Q-L-G

wherein Q represents

wherein X 1 and X 2 are independently alkoxy, optionally substituted amino, halo, haloalkyl or hydroxyl; n is from 0 to 2; m is from 0 to 4; and R 1 is H, alkyl, heteroalkyl, or alkylamino;

wherein L is a hydrocarbon chain containing from 1 to 12 carbon atoms, optionally branched;

and wherein G is a CQ R reversal moiety having a formula selected from the structure

wherein

X 4 is N, and R 6 and R 7 are independently aralkyl, heteroaryl alkyl, or heterocyclyl alkyl, or

X 4 is NHCH, R 6 and R 7 are aryl or heteroaryl and R 6 and R 7 together with X 4 form a tricyclic ring system.

2. The compound of claim 1 , having a formula selected from

3. A pharmaceutical composition, the composition comprising a therapeutically effective amount of the compound of claim 1 and a pharmaceutically acceptable carrier.

4. The pharmaceutical composition of claim 3 further comprising at least one additional medicinal or pharmaceutical agent.

5. The pharmaceutical composition of claim 4 , wherein the additional medicinal or pharmaceutical agent is an antimalarial therapeutic agent.

6. The pharmaceutical composition of claim 4 , wherein the at least one additional medicinal or pharmaceutical agent is selected from the group consisting of artesunate, mefloquine, sulfadoxine, pyrimethamine, and combinations thereof.

Assignments (2)
CONFIRMATORY LICENSE Recorded Dec 27, 2016
From: PORTLAND STATE UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 041188/0783 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 30, 2014
From: PEYTON, DAVID H.; BURGESS, STEVEN
To: STATE OF OREGON ACTING BY AND THROUGH THE STATE BOARD OF HIGHER EDUCATION ON BEHALF OF PORTLAND STATE UNIVERSITY
Reel/Frame 032088/0921 →
Continuity (3)
Division 11884547
Provisional Application 60654207 · Feb 17, 2005
Related Publication 20110257160A1 · Oct 20, 2011